User contributions
Jump to navigation
Jump to search
- 13:38, 23 October 2021 diff hist +183 m Esophageal cancer →Definitive therapy current
- 12:14, 21 October 2021 diff hist -85 m Regimen naming conventions (nomenclature) →Regimens Built on an Existing Two-Drug Backbone current
- 12:12, 21 October 2021 diff hist +9 m Regimen naming conventions (nomenclature) →Examples
- 21:30, 18 October 2021 diff hist +53 m Drug index →P current
- 14:16, 17 October 2021 diff hist +1,433 m Mantle cell lymphoma - null regimens →Maintenance after first-line therapy current
- 12:58, 17 October 2021 diff hist +1,045 m B-cell acute lymphoblastic leukemia, pediatric →DOLP {{#subobject:3c9897|Regimen=1}} current
- 01:12, 17 October 2021 diff hist +1,860 m Renal cell carcinoma current
- 01:06, 17 October 2021 diff hist +31 m Head and neck cancer →References current
- 01:04, 17 October 2021 diff hist +1,263 m Ovarian cancer →Doxorubicin pegylated liposomal monotherapy {{#subobject:cd6479|Regimen=1}} current
- 00:46, 17 October 2021 diff hist +33 m Mantle cell lymphoma →References current
- 00:42, 17 October 2021 diff hist +728 m Follicular lymphoma →Bendamustine monotherapy {{#subobject:ebf543|Regimen=1}} current
- 18:50, 16 October 2021 diff hist +796 N Lutetium-177-PSMA-617 Created page with "==Preliminary data== #'''VISION:''' Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour..." current
- 18:47, 16 October 2021 diff hist +27 m Drug index →L
- 18:43, 16 October 2021 diff hist +612 m Multiple myeloma, relapsed-refractory →Relapsed or refractory, other combinations current
- 17:15, 15 October 2021 diff hist +1,024 m Non-small cell lung cancer →Atezolizumab monotherapy {{#subobject:41gac4|Regimen=1}}
- 17:10, 15 October 2021 diff hist +31 m Atezolizumab (Tecentriq) →Non-small cell lung cancer current
- 17:10, 15 October 2021 diff hist +300 m Atezolizumab (Tecentriq) →Non-small cell lung cancer
- 14:57, 15 October 2021 diff hist +101 m WHIM syndrome current
- 14:57, 15 October 2021 diff hist +101 m Thrombocytopenia in liver disease current
- 14:57, 15 October 2021 diff hist +101 m Immune thrombocytopenia current
- 14:57, 15 October 2021 diff hist +101 m Autoimmune cytopenia current
- 14:57, 15 October 2021 diff hist +101 m Aplastic anemia current
- 22:48, 14 October 2021 diff hist +2,188 m Multiple myeloma, consolidation and maintenance →Daratumumab monotherapy {{#subobject:744fd9|Regimen=1}} current
- 22:47, 14 October 2021 diff hist -1 m Multiple myeloma, induction →Subsequent treatment current
- 20:15, 14 October 2021 diff hist +1,603 m Breast cancer, triple negative →Capecitabine monotherapy {{#subobject:e058c1|Regimen=1}} current
- 13:47, 14 October 2021 diff hist +991 m Hepatocellular carcinoma →Sorafenib monotherapy {{#subobject:b38f69|Regimen=1}} current
- 13:38, 14 October 2021 diff hist +1,293 m Prostate cancer - historical →References current
- 13:37, 14 October 2021 diff hist -110 m Prostate cancer →ADT & RT {{#subobject:514ac2|Regimen=1}} current
- 13:37, 14 October 2021 diff hist +11 m Prostate cancer →References
- 13:35, 14 October 2021 diff hist +781 m Prostate cancer →ADT & RT {{#subobject:514ac2|Regimen=1}}
- 20:45, 13 October 2021 diff hist +9,260 Cervical cancer →Persistent, recurrent, or metastatic disease, first-line therapy current
- 15:25, 13 October 2021 diff hist +6,678 m Cervical cancer →Persistent, recurrent, or metastatic disease, first-line therapy
- 15:04, 13 October 2021 diff hist +271 m Pembrolizumab (Keytruda) →Cervical cancer current
- 12:10, 13 October 2021 diff hist +753 m Graft versus host disease →Cyclosporine & Methotrexate current
- 01:22, 13 October 2021 diff hist +1,305 m Esophageal squamous cell carcinoma →Metastatic or locally advanced disease, first-line current
- 01:11, 13 October 2021 diff hist +2,100 m Non-small cell lung cancer →Adjuvant therapy
- 01:10, 13 October 2021 diff hist +1,593 m Non-small cell lung cancer →Cisplatin & Gemcitabine (GC) {{#subobject:289ea6|Regimen=1}}
- 01:04, 13 October 2021 diff hist +2,063 Non-small cell lung cancer →Carboplatin & Paclitaxel (CP) {{#subobject:3a6ad9|Regimen=1}}
- 00:52, 13 October 2021 diff hist +228 m Non-small cell lung cancer →Atezolizumab monotherapy {{#subobject:412fc4|Regimen=1}}
- 12:01, 12 October 2021 diff hist +30 m Non-small cell lung cancer, Nonsquamous →References
- 12:00, 12 October 2021 diff hist -89 m Non-small cell lung cancer, EGFR-mutated →Cisplatin & Pemetrexed {{#subobject:af12b4|Regimen=1}}
- 12:42, 9 October 2021 diff hist +644 m Nasopharyngeal carcinoma →Cisplatin & Gemcitabine (GC) {{#subobject:65069f|Regimen=1}} current
- 12:40, 9 October 2021 diff hist +594 m Toripalimab (JS001) current
- 11:55, 7 October 2021 diff hist +1,182 m Non-small cell lung cancer, EGFR-mutated
- 18:20, 2 October 2021 diff hist +183 m Brexucabtagene autoleucel (Tecartus) →History of changes in FDA indication current
- 18:19, 2 October 2021 diff hist +121 m B-cell acute lymphoblastic leukemia →Brexucabtagene autoleucel monotherapy {{#subobject:4z3u14|Regimen=1}} current
- 17:22, 2 October 2021 diff hist +11 m User:Wayneliang
- 13:30, 23 September 2021 diff hist +688 m Cholangiocarcinoma →Infigratinib monotherapy {{#subobject:afgh1g|Regimen=1}} current
- 13:27, 23 September 2021 diff hist +41 m Esophageal cancer →Cisplatin & Fluorouracil (CF) & Pembrolizumab {{#subobject:c798a3|Regimen=1}}
- 21:02, 22 September 2021 diff hist +1,554 Cervical cancer →Pemetrexed monotherapy {{#subobject:57456b|Regimen=1}}